AU2021376374A1 - Use of isatuximab for the treatment of multiple myeloma - Google Patents

Use of isatuximab for the treatment of multiple myeloma Download PDF

Info

Publication number
AU2021376374A1
AU2021376374A1 AU2021376374A AU2021376374A AU2021376374A1 AU 2021376374 A1 AU2021376374 A1 AU 2021376374A1 AU 2021376374 A AU2021376374 A AU 2021376374A AU 2021376374 A AU2021376374 A AU 2021376374A AU 2021376374 A1 AU2021376374 A1 AU 2021376374A1
Authority
AU
Australia
Prior art keywords
individual
month
antibody
administering
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021376374A
Other languages
English (en)
Inventor
Dorothee Semiond
Hoai-Thu THAI
Helgi Van De Velde
Christine VEYRAT-FOLLET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis US LLC filed Critical Sanofi Aventis US LLC
Publication of AU2021376374A1 publication Critical patent/AU2021376374A1/en
Assigned to SANOFI-AVENTIS U.S. LLC reassignment SANOFI-AVENTIS U.S. LLC Request for Assignment Assignors: SANOFI-AVENTIS U.S. LLC, SEMIOND, DOROTHEE, THAI, Hoai-Thu, VAN DE VELDE, HELGI, VEYRAT-FOLLET, Christine
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021376374A 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma Pending AU2021376374A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063109305P 2020-11-03 2020-11-03
US63/109,305 2020-11-03
US202163239108P 2021-08-31 2021-08-31
US63/239,108 2021-08-31
PCT/US2021/072193 WO2022099257A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
AU2021376374A1 true AU2021376374A1 (en) 2023-06-29

Family

ID=78825149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021376374A Pending AU2021376374A1 (en) 2020-11-03 2021-11-02 Use of isatuximab for the treatment of multiple myeloma

Country Status (8)

Country Link
US (1) US20220135696A1 (https=)
EP (1) EP4240416A1 (https=)
JP (1) JP2023550311A (https=)
AU (1) AU2021376374A1 (https=)
CA (1) CA3197381A1 (https=)
IL (1) IL302640A (https=)
TW (1) TW202233235A (https=)
WO (1) WO2022099257A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279065B2 (ja) 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3421494A1 (en) * 2017-06-29 2019-01-02 Sanofi Use of isatuximab in combination with an anti-pd-1 antibody
KR20210006321A (ko) * 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
US11939390B2 (en) * 2019-01-28 2024-03-26 Sanofi-Aventis U.S. Llc Methods of treating multiple myeloma
WO2020212912A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Combination therapies comprising daratumumab, bortezomib, thalidomide and dexamethasone and their uses
US20210171650A1 (en) * 2019-05-14 2021-06-10 Sanofi Methods of administering anti-cd38 antibody

Also Published As

Publication number Publication date
JP2023550311A (ja) 2023-12-01
WO2022099257A1 (en) 2022-05-12
CA3197381A1 (en) 2022-05-12
TW202233235A (zh) 2022-09-01
EP4240416A1 (en) 2023-09-13
US20220135696A1 (en) 2022-05-05
IL302640A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
Mould et al. Drug development of therapeutic monoclonal antibodies
Mould et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development
CN106102767B (zh) 用于诊断和治疗炎症性肠病的方法
JP7712206B2 (ja) 多発性骨髄腫の処置方法
US20190336496A1 (en) Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
HK1213522A1 (zh) 用於诊断和治疗炎性肠病的方法
US20230133118A1 (en) Compositions and methods for treating cancer
US20230074793A1 (en) Treatment with a bispecific antibody that binds ctla4 and pd1
US20240076382A1 (en) CD1a ANTIBODIES AND USES THEREOF
CA3152263A1 (en) Composite biomarker for cancer therapy
WO2022060955A1 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
KR20200033930A (ko) 체크포인트 억제제에 대한 예측성 말초 혈액 바이오마커
WO2022099257A1 (en) Use of isatuximab for the treatment of multiple myeloma
CN116761627A (zh) 艾萨妥昔单抗用于治疗多发性骨髓瘤的用途
HK40059862A (en) Methods for diagnosing and treating inflammatory bowel disease
WO2025109518A1 (en) Methods for treatment of myeloproliferative neoplasms
AU2013237638B2 (en) Anti-kir antibodies, formulations, and uses thereof
Paintaud et al. Monoclonal antibodies for therapeutic use: Specific characteristics of clinical development, evaluation by the agencies, and long-term monitoring of safety
van Lümig Effectiveness and tolerability of extended biologic treatment for psoriasis in daily practice
HK1230521B (zh) 用於诊断和治疗炎症性肠病的方法
HK1230521A1 (en) Methods for diagnosing and treating inflammatory bowel disease

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SANOFI-AVENTIS U.S. LLC

Free format text: FORMER APPLICANT(S): SEMIOND, DOROTHEE; VEYRAT-FOLLET, CHRISTINE; SANOFI-AVENTIS U.S. LLC; THAI, HOAI-THU; VAN DE VELDE, HELGI